A5069365250- SARS-CoV-2 and COVID-19 Research
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Electrolyte and hormonal disorders
- CAR-T cell therapy research
- Crystallization and Solubility Studies
- Immune Cell Function and Interaction
- X-ray Diffraction in Crystallography
- Chronic Lymphocytic Leukemia Research
- Cytomegalovirus and herpesvirus research
- Platelet Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood groups and transfusion
- CNS Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- COVID-19 Clinical Research Studies
- Autoimmune Neurological Disorders and Treatments
- Vascular Tumors and Angiosarcomas
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune responses and vaccinations
- Neurological and metabolic disorders
- Immune cells in cancer
- Viral-associated cancers and disorders
- Colorectal Cancer Treatments and Studies
Hokkaido University
2024
Kisarazu Hospital
2022-2023
Sapporo Hokuyu Hospital
2021-2022
Chiba University Hospital
2012
Data on the response to COVID-19 vaccine in patients with myeloid malignancy, who are at severe risk case of infection, have not emerged. In a study 69 malignancies, including 46 acute leukaemia (AML) and 23 myelodysplastic syndrome (MDS), anti-spike SARS-CoV-2 antibody titres were measured 3 months after second mRNA-based vaccination. Seroconversion rates for AML MDS 94.7% 100% respectively, no significant difference from healthy controls (HCs). Patients showed significantly lower titre...
Serologic responses of COVID-19 vaccine are impaired in patients with B-cell lymphoma, especially those who had recently been treated anti-CD20 monoclonal antibodies. However, it is still unclear whether develop an immune response following vaccination. We investigated the efficacy vaccination against SARS-CoV-2 171 non-Hodgkin lymphoma (B-NHL) received two doses mRNA-based and we compared to that 166 healthy controls. Antibody titers were measured 3 months after administration second dose....
It has been suggested that the effect of coronavirus disease 2019 (COVID-19) booster vaccination in patients with B-cell non-Hodgkin’s lymphoma (B-NHL) is inferior to healthy individuals. However, differences according histological subtype or treatment status are unclear. In addition, there less research on who subsequently develop breakthrough infections. We investigated effects first COVID-19 for B-NHL and clinical features infections Omicron variant era. this study, was classified into...
Abstract Severe hyponatremia is a critical electrolyte abnormality in allogeneic stem cell transplantation (allo‐ SCT ) recipients and >50% of cases severe are caused by the syndrome inappropriate secretion antidiuretic hormone ( SIADH ). Here, we present patient with rapidly progressive as an initial sign symptom human herpesvirus‐6–associated post‐transplantation acute limbic encephalitis HHV ‐6 PALE after allo‐ . A 45‐year‐old woman lymphoblastic leukemia received unrelated bone marrow...
Duodenal-type follicular lymphoma (D-FL) has been recognized as a rare entity that accounts for approximately 4% of primary gastrointestinal lymphomas. D-FL follows an indolent clinical course compared with common nodal FL and is generally considered to have better prognosis. Therefore, the "watch wait" approach frequently adopted treatment method. Alternatively, there option actively intervene in D-FL. However, long-term outcomes such cases are poorly understood.To clarify after follow-up...
We have reported that seroconversion rates after the second dose of mRNA-based COVID-19 vaccines for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were 100% 95% respectively, with no significant difference from healthy controls (HCs).However, there are very limited data response to a third vaccine in those patients.In this complementary study, we investigated booster effect patients malignancies.A total 58 including 20 MDS 38 AML enrolled. Anti-SARS-CoV-2S immunoassays...
Abstract Patients with lymphoid malignancies have impaired humoral immunity caused by the disease itself and its treatment, placing them at risk for severe coronavirus disease-19 (COVID-19) reduced response to vaccination. However, data COVID-19 vaccine responses in patients mature T cell NK-cell neoplasms are very limited. In this study of 19 T/NK-cell neoplasms, anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike antibodies were measured 3 months, 6 9 months after...
The standard treatment for colorectal mucosa-associated lymphoid tissue (MALT) lymphoma has not yet been established due to the rarity of disease. Here, we report a case long-term response chemotherapy MALT (stage I). A 77-year-old frail female patient with diabetes mellitus and dementia developed melena unknown etiology, colonoscopy was performed at nearby hospital. biopsy suggested malignant lymphoma, she referred our department. As result re-examination colonoscopy, total 3 submucosal...
Data for COVID-19 vaccine response in patients with immune thrombocytopenia (ITP) are very limited. In a study of 28 ITP, anti-severe acute respiratory syndrome coronavirus 2 spike antibody titres were measured after vaccination. The seroconversion rate ITP was 91.3%, comparable to that healthy controls (HCs). However, the titre significantly lower than HCs and declined ageing. Furthermore, who received minimum prednisolone dose at least 5 mg/day any time-point or initial vaccination other patients.
Abstract Background In patients with hepatitis C virus (HCV) and malignant lymphoma, flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing have not been established, this issue is complicated by conflicting results regarding the use direct-acting antivirals uncontrolled malignancies. Case presentation We report first case effective safe treatment on-demand 8-week glecaprevir pibrentasvir a patient diffuse large B-cell...
Background: The end of the pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), virus responsible for disease-19 (COVID-19), is not foreseen. Vaccination using two subtypes mRNA-based vaccines, BNT162b2 or mRNA-1273, an effective public health measure to reduce risk infection and complications from COVID-19. However, COVID-19 vaccine response data patients with myeloid malignancy, who are at in case infection, has emerged. Aims: We investigated antibody titers malignancies...
Abstract Human herpes virus-6 (HHV-6) encephalitis is one of the life-threatening complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early diagnosis and intervention are important for prevention poor prognosis sequelae. Although hyponatremia known to be associated with HHV-6 encephalitis, it unclear whether preceding a useful hallmark encephalitis. We retrospectively reviewed 134 consecutive patients who underwent allo-HSCT at our institution evaluated...